Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53

The TP53 tumor suppressor is mutated in ~75% of pancreatic cancers. The mutant TP53 protein in pancreatic ductal adenocarcinomas (PDAC) promotes tumor growth and metastasis. Attempts have been made to develop molecules that restore at least some of the properties of wild-type (WT) TP53. APR-246 is o...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Stephen L. Abrams, Przemysław Duda, Shaw M. Akula, Linda S. Steelman, Matilde L. Follo, Lucio Cocco, Stefano Ratti, Alberto M. Martelli, Giuseppe Montalto, Maria Rita Emma, Melchiorre Cervello, Dariusz Rakus, Agnieszka Gizak, James A. McCubrey
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2022-02-01
Saila:Cells
Gaiak:
TP53
mutant TP53 reactivators
nutlin-3a
targeted therapy
PDAC
Sarrera elektronikoa:https://www.mdpi.com/2073-4409/11/5/794

Internet

https://www.mdpi.com/2073-4409/11/5/794

Antzeko izenburuak